Management of gynecomastia in adolescence and adults: the clinical practice guidelines from the Italian Society of Andrology and Sexual Medicine (SIAMS).

Standardizing the Male Breast: New Clinical Pathways for Gynecomastia

Gynecomastia—the benign proliferation of glandular tissue in the male breast—is a widespread clinical reality. It affects anywhere from 4% to 69% of the population depending on age and health. It is common in both adolescence and adulthood. It often brings significant physical discomfort and profound psychological distress. Historically, clinical management has been inconsistent. Practitioners often oscillate between superficial assessments and unnecessary, expensive investigations.

A new consensus statement from the Italian Society of Andrology and Sexual Medicine (SIAMS) aims to resolve this fragmentation. A multidisciplinary expert panel developed updated clinical practice guidelines. These guidelines move away from "one-size-fits-all" reactions. They provide a structured, evidence-based framework. The goal is to provide doctors with a clear roadmap. They must decide when to observe, when to medicate, and when to operate.

The Failure of Inconsistent Management

Before these guidelines, the clinical approach lacked a unified hierarchy of action. Gynecomastia can be triggered by many factors. These range from transient developmental phases in puberty to life-threatening hormone-secreting tumors. Clinicians faced a dilemma of diagnostic depth. Without a standardized protocol, many patients suffered from two extremes. Some faced over-medicalization. Healthy adolescents underwent exhaustive hormonal panels for transient physiological changes. Others faced under-diagnosis. Subtle signs of malignancy in older men were sometimes overlooked.

The difficulty lies in the complexity of the etiology (the study of causation). Gynecomastia is not a single disease. It is a manifestation of various disruptions in endocrine balance. This involves the antagonistic relationship between androgens (male sex hormones like testosterone) and estrogens (female sex hormones). This balance can be tipped by drugs, obesity, kidney disease, or genetic mutations. A haphazard diagnostic approach is inherently risky.

A Tiered Architecture for Diagnosis

The SIAMS guidelines implement a structured diagnostic and therapeutic algorithm, as visualized in . The framework prioritizes a logical decomposition of the problem into five categories: physiological, pharmacological, pathological, congenital, and genetic.

The mechanism of the new approach relies on a strict hierarchical workflow:

1. Initial Clinical Assessment: This is the cornerstone of the process. It requires a thorough medical history and physical examination. This step distinguishes true gynecomastia from pseudogynecomastia (lipomastia). Lipomastia is characterized by excessive fat deposition without glandular proliferation.
2. Ruling Out Physiology: Clinicians must first rule out "normal" hormonal shifts. These include transient enlargement in neonates due to maternal hormones. It also includes common occurrences during puberty. It includes age-related shifts in the estrogen-to-androgen ratio in older men.
3. Targeted Etiological Work-up: If the cause is not physiological, the clinician moves to laboratory assessment. The paper recommends a "first-line" panel. This consists of LH (luteinizing hormone), total testosterone, SHBG (sex hormone-binding globulin), albumin, prolactin, and $\beta$-hCG (a biomarker often elevated in testicular tumors).
4. Imaging Integration: Imaging is not used universally. It is reserved for equivocal cases or when malignancy is suspected. The guidelines suggest ultrasound as the primary tool for men under 35. They recommend mammography if the physical exam strongly suggests breast cancer.

As shown in, ultrasound can further refine the diagnosis. It identifies specific morphological patterns. These include the "nodular" pattern (early/florid phase), the "dendritic" pattern (intermediate/fibroglandular phase), and the "diffuse" pattern (chronic/fibrotic phase).

Quantifying Clinical Efficacy

The guidelines are built upon a systematic review of existing literature. The authors utilized the GRADE system to rank the certainty of evidence. The paper highlights several key metrics regarding medication. These focus on preventing side effects in cancer patients.

In patients undergoing androgen ablation therapy (treatment to suppress testosterone) for prostate cancer, the paper reports significant results. This therapy uses bicalutamide. One study found that 20 mg of daily tamoxifen resulted in 0% incidence of gynecomastia. This was compared to a 33% incidence in the placebo group. Another study reported a dose-dependent effect. In that study, the 20 mg tamoxifen group saw only 14.7% incidence. This was compared to 81.7% in the placebo group. These numbers show that tamoxifen can effectively prevent breast enlargement in these patients.

The paper also notes the limitations of other medical interventions. In a randomized trial of eighty boys with pubertal gynecomastia, anastrozole (an aromatase inhibitor) was tested. The response rate was 38.5%. This was not statistically significant compared to the 31.4% response in the placebo group. This suggests that medical therapy is not a guaranteed solution for all glandular enlargement.

Limitations and Uncertainties

The SIAMS guidelines provide much-needed structure. However, the authors are transparent about their limitations. There is a scarcity of high-quality, comparative studies. Many recommendations rely on expert consensus. This applies to the optimal dosage and duration of therapies like tamoxifen or dihydrotestosterone. These are not always backed by large-scale randomized controlled trials (RCTs).

The "watchful waiting" period remains a gray area. The guidelines suggest observation for new-onset pubertal or idiopathic cases. Yet, there is no definitive consensus on the exact duration. Clinicians do not have a fixed timeline to decide when a case becomes "persistent." This persistence would trigger surgical or medical intervention. Finally, the psychological impact is massive. However, the existing scientific literature on psychosocial interventions remains thin. It lacks standardized assessment tools.

The Verdict: A Necessary Scaffold

The SIAMS guidelines are a definitive step toward clinical standardization. They do not claim to have discovered a cure. Instead, they provide the essential scaffolding for better care. This framework helps stop the cycle of unnecessary testing and missed diagnoses. It prioritizes the distinction between physiological shifts and pathological growths. This protects patients from the costs of over-treatment and the dangers of medical neglect.

For the practitioner, the takeaway is clear. Start with the patient's history. Master the art of palpation to rule out simple fat deposition. Only escalate to complex hormonal or imaging investigations when the clinical picture demands it. The era of treating every case of male breast enlargement with the same aggressive diagnostic battery is ending.

Figures from the paper